Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Targanta’s Noninferiority Study Design Could Be Regulatory Hurdle For Oritavancin

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Targanta may need to conduct additional clinical trials of its intravenous antibiotic oritavancin if FDA does not accept the company's use of a 15 percent noninferiority delta in its Phase III trial, according to the firm's initial public offering prospectus filed May 11 with the Securities & Exchange Commission.

You may also be interested in...

Jazz submits complete responses for Luvox

Jazz Pharmaceuticals announces FDA's acceptance of a complete response to an "approvable" letter for Luvox CR (fluvoxamine maleate extended-release capsules), setting a user fee date at December 22. The NDA seeks claims for treatment of obsessive compulsive disorder and social anxiety disorder. FDA also has accepted the submission of Solvay Pharmaceuticals' complete response to its approvable letter for Luvox immediate-release tablets, setting the action date at December 21. Jazz licensed U.S. marketing rights to Luvox CR and Luvox from Solvay in January. Jazz expects to launch Luvox CR in the U.S. during the first quarter of 2008. The firm had its initial public offering in May (1Pharmaceutical Approvals Monthly June 2007, p. 6)...

Licensing In Brief

Pfizer ups ante on Exubera approval with full license: Pfizer's decision to acquire Sanofi-Aventis' marketing rights to Exubera suggests the company is confident that the inhaled insulin product will receive FDA approval. Exubera's user fee date is Jan. 27, following a three-month extension resulting from an FDA request for additional technical chemistry data. Pfizer announced Jan. 12 that it will acquire worldwide rights for the development, production and commercialization of Exubera for $1.3 bil. - building on the firms' previous co-development alliance. The deal follows a judge's ruling that Sanofi's purchase of Aventis constituted a change-in-control under Pfizer and Aventis' 1998 agreement for Exubera. The NDA was submitted in March (1Pharmaceutical Approvals Monthly March 2005, p. 12)...

Asia Spotlight: Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China

Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts